Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m2, and chronic kidney disease – A randomised, controlled pilot study
Authors' conclusion
In patients with type 1 diabetes, BMI > 25 kg/m2, and chronic kidney disease, the combining GLP-1 + SGLT2i + lifestyle modification was safe and produced significant weight loss but did not significantly improve metabolic and blood pressure control.
Study context
- Population
- Patients with T1D, BMI > 25 kg/m², and early CKD
- Participants
- 60 patients
- Comparison
- GLP-1, SGLT2i, GLP-1 + SGLT2i, or GLP-1 + SGLT2i + lifestyle modification vs usual care
- Usual caren = 12reference
- Primary endpoint
- Change in bodyweight
- Follow-up
- 6 months
Methodological detailssingle-centre, pilot
- Single-centre
- Pilot
Primary result
As reported in the abstract
Bodyweight change
Difference, % (95% CI)P value
GLP-1 + SGLT2i + lifestylevs Usual care
−9.6(−14.4 to −4.9)
P < 0.001Difference (95% CI)P value
GLP-1 + SGLT2i + lifestylevs SGLT2i
−8.0(−12.6 to −3.4)
P = 0.002Secondary outcomes
Glycaemia and BP
- No significant differences in glycaemia or BP among groups
Urine albumin creatinine ratio, GLP-1 + SGLT2i + lifestyle
- Reduction from baseline (95% CI 500.7, 1069.1) to (95% CI −1.6, 576.8); p < 0.001
- 784.9mg/g to 287.6mg/g
Safety
Adverse events
- Adverse events: n = 6/12 usual care; n = 24/48 medication groups
Original publication
Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m2, and chronic kidney disease – A randomised, controlled pilot study. Diabetes Res Clin Pract. Published 21 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →